AMENDED AND RESTATED DEVELOPMENT SERVICES AND CLINICAL SUPPLY AGREEMENT by and between PASSAGE BIO, INC. and CATALENT MARYLAND, INC. Dated as of November 9, 2023Development Services and Clinical Supply Agreement • March 4th, 2024 • Passage BIO, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED DEVELOPMENT SERVICES AND CLINICAL SUPPLY AGREEMENT (this “Agreement”), dated as of the 9th day of November, 2023, (the “Amendment Effective Date”), is entered into by and between PASSAGE BIO, INC., a corporation organized and existing under the Laws of Delaware and having a place of business at One Commerce Square, 2005 Market Street, 39th Floor, Philadelphia, Pennsylvania 19193 (“Passage Bio”), and CATALENT MARYLAND, INC. (formerly PARAGON BIOSERVICES, INC.), a corporation organized and existing under the Laws of Delaware and having a place of business at 801 West Baltimore Street, Suite 302, Baltimore, Maryland 21201 (“Catalent”). Passage Bio and Catalent are sometimes referred to herein, individually, as a “Party” and collectively as the “Parties.”
DEVELOPMENT SERVICES AND CLINICAL SUPPLY AGREEMENT Between GLAXOSMITHKLINE LLC And UNIGENE LABORATORIES, INC.Development Services and Clinical Supply Agreement • November 9th, 2011 • Unigene Laboratories Inc • Medicinal chemicals & botanical products • Pennsylvania
THIS DEVELOPMENT SERVICES AGREEMENT (this “Agreement”) is entered into as of this August 3, 2011 (the “Effective Date”), by and between GlaxoSmithKline LLC, a Delaware limited liability company (“GSK”), and Unigene Laboratories, Inc., a Delaware corporation (“Unigene”). GSK and Unigene are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
